Fibroblast growth factors in control of lipid metabolism

Struik, Dicky; Dommerholt, Marleen B; Jonker, Johan W

Published in:
Current Opinion in Lipidology

DOI:
10.1097/MOL.0000000000000599

REVIEW

OPEN

Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application

Dicky Struik, Marleen B. Dommerholt, and Johan W. Jonker

Purpose of the review
Several members of the fibroblast growth factor (FGF) family have been identified as key regulators of energy metabolism in rodents and nonhuman primates. Translational studies show that their metabolic actions are largely conserved in humans, which led to the development of various FGF-based drugs, including FGF21-mimetics LY2405319, PF-05231023, and pegbelfermin, and the FGF19-mimetic NGM282. Recently, a number of clinical trials have been published that examined the safety and efficacy of these novel therapeutic proteins in the treatment of obesity, type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and cholestatic liver disease. In this review, we discuss the current understanding of FGFs in metabolic regulation and their clinical potential.

Recent findings
FGF21-based drugs induce weight loss and improve dyslipidemia in patients with obesity and T2D, and reduce steatosis in patients with NASH. FGF19-based drugs reduce steatosis in patients with NASH, and ameliorate bile acid-induced liver damage in patients with cholestasis. In contrast to their potent antidiabetic effects in rodents and nonhuman primates, FGF-based drugs do not appear to improve glycemia in humans. In addition, various safety concerns, including elevation of low-density lipoprotein cholesterol, modulation of bone homeostasis, and increased blood pressure, have been reported as well.

Summary
Clinical trials with FGF-based drugs report beneficial effects in lipid and bile acid metabolism, with clinical improvements in dyslipidemia, steatosis, weight loss, and liver damage. In contrast, glucose-lowering effects, as observed in preclinical models, are currently lacking.

Keywords
bile acid metabolism, FGF1, FGF19, FGF21, fibroblast growth factors, lipid metabolism

INTRODUCTION

Fibroblast growth factor (FGF)15/19, FGF21, and more recently FGF1 have emerged as key regulators of bile acid, lipid, and carbohydrate metabolism [1–3]. These 'metabolic FGFs' are members of the FGF superfamily, which consists of 18 closely related genes, and of which the encoded proteins can be functionally classified as autocrine/paracrine or endocrine acting growth factors [4]. FGF1 is an autocrine/paracrine growth factor that binds locally to cell surface heparan sulfate proteoglycans (HSPG) [5]. FGF19 and FGF21 have reduced affinity for HSPG, which allows them to escape into the circulation and act as endocrine hormones [6]. Instead of binding to HSPG, endocrine FGFs bind to the transmembrane protein β-klotho (KLB) [6]. Recruitment of FGFs by HSPG or KLB promotes FGF receptor (FGFR) transphosphorylation, followed by activation of various signaling cascades, including the mitogen-activated protein kinase, phosphatidylinositol 3-kinase-protein kinase B, phospholipase C gamma, and signal transducer and activator of transcription (STAT) pathways [4]. In both humans and mice, four FGFR genes (FGFR1–4) have been identified, which differ in their ligand-binding

Department of Pediatrics, Section of Molecular Metabolism and Nutrition, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Correspondence to Johan W. Jonker, Department of Pediatrics, Section of Molecular Metabolism and Nutrition, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, the Netherlands. E-mail: j.w.jonker@umcg.nl

Curr Opin Lipidol 2019, 30:000–000

DOI:10.1097/MOL.0000000000000599

KEY POINTS

- FGFs potently interfere with bile acid, lipid, and carbohydrate metabolism in rodents and nonhuman primates.
- Translational studies support a role for FGFs in metabolic regulation and disease in humans.
- Clinical studies demonstrate that FGF-based drugs effectively ameliorate dyslipidemia, hepatic steatosis, and bile acid-related liver damage, whereas their glycemic actions are not recapitulated in humans.

specificities [7]. As FGFs and FGFRs are ubiquitously expressed and regulate basic cellular functions, including growth, proliferation, and differentiation [8], many FGF/FGFR mutations lead to defective embryonic development [4]. However, the phenotypes of *Fgf15*, *Fgf21*, and *Fgf1* knockout mice revealed that these genes also play important roles postnatally in controlling metabolic homeostasis [9–11]. The metabolic function of these genes is also highlighted by their identification as targets of nutrient-sensitive transcription factors, including farnesoid X receptor (FXR) and peroxisome proliferator-activated receptors alpha and gamma (PPARα, PPARγ) [1]. Translational studies further demonstrated that FGFs regulate similar metabolic pathways in humans, which led to the development of various FGF-based drugs, of which the safety and efficacy are currently being evaluated [3]. In this review, we will give an overview of the current understanding of FGFs in metabolic regulation (Fig. 1) and discuss the therapeutic effects of FGF-based drugs in human disease (Table 1).

FIBROBLAST GROWTH FACTOR 15/19: BIOLOGICAL FUNCTIONS

Despite the low sequence similarity between mouse *Fgf15* and its human orthologue *Fgf19* [12,13], their genes are syntenic and their biological function in the regulation of bile acid homeostasis is conserved [9,14]. Postprandial release of bile acids activates ileal FXR and results in the production of FGF15/19 [9,14]. Once secreted, FGF15/19 travels to the liver where it



FIGURE 1. The physiological and pharmacolgical actions of FGF19, FGF21, and FGF1 are driven by activation of FGFRs in different target organs. This figure was created using Servier Medical Art (http://smart.servier.com/).

Table 1. Key findings of clinical trials using FGF-based drugs

FGF-based drug	Dose	Disease	Key findings	Reference
NGM282 (FGF19)	3 mg/day (7 days)	Healthy volunteers	↓C4 and serum BAs	[40]
	3 or 6 mg/day (12 weeks)	NASH	↓Liver fat content, ALT, AST, C4, Pro-C3, TIMP-1, triglycerides, body weight ↑ LDL	[42▪▪]
	0.3 or 3 mg/day (28 days)	PBC	↓ALP, GGT, ALT, AST, LDL, C4, IgM, IgG, GCA	[47▪▪]
	1 or 6 mg/day (14 days)	Functional constipation	↓GE $T_{1/2}$, fecal Bas ↑Colonic transit, #bowel movements, stool form, ease of passage	[49▪]
	1 or 3 mg/day (12 weeks)	PSC	↓ C4, serum BAs, ALT, AST, GGT, pro-C3, PIIINP	[48▪▪]
NGM282+ rosuvastatin (FGF19)	0.3, 1 or 3 mg/day (12 weeks) +20–40 mg/day (10 weeks)	NASH	↓7-Alpha-hydroxy-4-cholesten-3-one, serum BA, triglycerides, total cholesterol, LDL, liver fat content ↑ HDL	[44▪▪]
LY2405319 (FGF21)	3, 10, or 20 mg/day (28 days)	T2D	↓ LDL, ApoA2, ApoB, ApoC3, triglycerides, total cholesterol, insulin, body weight ↑ HDL, adiponectin, β-hydroxybutyrate	[109]
PF-05231023 (FGF21)	0.5–200 mg/single dose	T2D	↓ Triglycerides, LDL, total cholesterol ↑ HDL	[110]
	5–140 mg (twice a week, for 5 weeks)	T2D	↓ Body weight, triglycerides, total cholesterol, LDL ↑ HDL, adiponectin, IGF-1	[113]
	25, 50, 100, or 150 mg (once weekly for 4 weeks)	Obese people	↓ Triglycerides ↑ HDL, adiponectin	[112▪]
BMS-986036 (FGF21)	10 mg daily or 20 mg weekly (for 16 weeks)	NASH	↓ Body fat, hepatic lipids, Triglycerides, LDL, ALT, AST, pro-C3 ↑adiponectin	[115▪▪]
	1, 5, 20 mg daily or 20 mg weekly (for 12 weeks)	Obesity and T2D	↓Triglycerides, pro-C3 ↑ HDL, adiponectin	[114]

ALP, alkaline phosphatase; *ALT*, alanine aminotransferase; *ApoA2*, apolipoprotein A2; *ApoB*, apolipoprotein B; *ApoC3*, apolipoprotein C-III; *AST*, aspartate aminotransferase; *Bas*, bile acids; *GCA*, glycocholic acid; *GE $T_{1/2}$*, gastric emptying; *GGT*, γ-glutamyl transpeptidase; *IGF-1*, insulin-like growth factor 1; *NASH*, nonalcoholic steatohepatitis; *PBC*, primary biliary cholangitis; *PIIINP*, N-terminal propeptide of type III collagen; *Pro-C3*, neoepitope-specific N-terminal pro-peptide of type III collagen; *PSC*, primary sclerosing cholangitis; *T2D*, type 2 diabetes; *TIMP-1*, tissue inhibitor of metalloproteinase 1.

binds the KLB/FGFR4 complex to inhibit the activity of cholesterol 7-α-hydroxylase (CYP7A1), the first and rate-limiting enzyme in the conversion of cholesterol to bile acids [9]. As bile acids are strong detergents, their synthesis needs to be tightly regulated to prevent enterohepatic damage [15]. As discussed later, the ability of FGF15/19 to inhibit bile acid synthesis is therapeutically exploited to prevent bile acid-induced tissue damage in cholestasis and nonalcoholic steatohepatitis (NASH).

FGF15/19 signaling also modulates lipid- and carbohydrate metabolism [16]. Transgenic mice that overexpress FGF19 display increased energy expenditure and are protected against diet-induced obesity and steatosis, at least partly by increasing fatty acid oxidation, but also by decreasing de-novo lipogenesis [17–20]. A role for FGF19 in glucose homeostasis is reflected by its ability to reduce plasma glucose levels in diabetic mice [21]. This glucose-lowering effect has been mechanistically linked to a glycogen synthase kinase 3-dependent increase in hepatic glycogen storage [22] and a cyclic adenosine monophosphate regulatory element binding protein/peroxisome proliferator-activated receptor γ coactivator-1α-dependent decrease in hepatic gluconeogenesis [23]. However, extrahepatic mechanisms, in particular KLB/FGFR1-dependent neuronal effects, also appear to contribute to FGF19-driven glucose lowering [24–26].

FIBROBLAST GROWTH FACTOR 19: HUMAN ASSOCIATION STUDIES

Altered plasma levels of FGF19 are observed in several physiological and pathophysiological states. Physiologically, FGF19 follows a diurnal rhythm and is increased postprandially following bile acid-induced FXR activation, as evidenced by the effects of primary bile acids and bile acid-binding resins that increase and decrease serum FGF19 levels, respectively [14]. Apart from its presence in

serum, FGF19 is expressed in cholangiocytes and secreted into human bile; yet, the physiological relevance of this is not known [27,28]. Reduced levels of FGF19 are generally observed in obesity and related disorders, including T2D, gestational diabetes, and nonalcoholic fatty liver disease (NAFLD) and NASH, but also in conditions of bile acid malabsorption such as cystic fibrosis [29–34]. During cholestasis, both hepatic and serum FGF19 are dramatically increased, indicating an adaptive response aimed to reduce bile acid-induced liver damage [34–36]. Although FGF19 levels sometimes normalize after bariatric surgery, its contribution to surgery-dependent diabetes remission is still debated [31,32,37].

FIBROBLAST GROWTH FACTOR 19: CLINICAL TRIALS

Although preclinical and translational studies with FGF19-mimetic drugs have shown promising results, the clinical application has been impeded by the fact that chronic FGF19 exposure in mice induces hepatocyte proliferation and the development of hepatocellular carcinomas, mediated through activation of the FGFR4/IL6/STAT3 pathway [38,39▪▪]. Extensive protein engineering produced a nonmitogenic FGF19 variant (NGM282, also referred to as M70) [19] which lacks FGFR4/IL6/STAT3 activity while retaining the ability to suppress CYP7A1 and bile acid synthesis in animal models [40]. A proof-of-concept study involving healthy volunteers examined the ability of NGM282 to suppress bile acid synthesis in humans and reported strongly reduced serum 7α-hydroxy-4-cholesten-3-one (C4) levels, a surrogate marker of hepatic CYP7A1 activity [41,42▪▪]. In the fed state, decreased serum C4 levels were associated with significantly lower serum bile acid concentrations, providing direct evidence of the role of the FGF19 pathway in human bile acid metabolism [40]. In a follow-up study, NGM282 was reported to have multiple beneficial effects in NASH. In this phase 2 trial, biopsy-confirmed NASH patients were treated with NGM282 for 12 weeks, which resulted in a clinically relevant decrease in liver fat content in up to 86% of the patients and this was accompanied by a reduction in plasma triglyceride levels and markers of liver damage and fibrosis [42▪▪]. In contrast to rodent studies, glucose, hemoglobin A1C (HbA1c), and insulin levels were unaffected [42▪▪,43]. A possible safety concern of NGM282 in NASH is its ability to increase plasma low-density lipoprotein cholesterol (LDLc) levels [42▪▪]. Nevertheless, NGM282-dependent elevations in cholesterol levels can be effectively managed by concomitant use of rosuvastatin [44▪▪].

Two recent studies evaluated the effect of NGM282 in patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), which are chronic liver diseases characterized by bile acid-induced liver damage and limited therapeutic options [45]. In PBC patients, NGM282 significantly reduced alkaline phosphatase (ALP) levels [46,47▪▪], a serum marker that strongly correlates with disease progression [48▪▪,49▪]. In addition, NGM282 also robustly reduced liver damage markers, including γ-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase, and lowered immunoglobulin levels, suggesting reduced disease-related immune activity [47▪▪]. Similarly, in PSC patients, NGM282 reduced serum levels of C4 levels, bile acids, and markers of liver damage and fibrosis [48▪▪]. However, plasma ALP levels were only transiently reduced [48▪▪].

Even though NGM282 was well tolerated in most patients, a dose-dependent increase in abdominal cramping and diarrhea was observed in all study populations [42▪▪,47▪▪,49▪]. This appears to be caused by an effect of NGM282 on bowel function, gastric emptying, and colonic transit and is speculated to be mechanistically unrelated to its effects on bile acids, but rather by actions on nerve cells [49▪]. In addition, rodent studies suggest that FGF19 can activate metabolic pathways that are utilized by FGF21 [24], indicating that additional mechanisms could play a role as well.

FIBROBLAST GROWTH FACTOR 21: BIOLOGICAL FUNCTIONS

The metabolic activity of FGF21 was originally discovered in a cell-based screen in which it stimulated glucose uptake in adipocytes [50]. Subsequent in-vivo studies demonstrated that FGF21 improved insulin sensitivity and lowered triglyceride levels in diabetic rodents [50]. Long-term FGF21 treatment largely recapitulates these metabolic improvements but also lowers body weight by enhancing energy expenditure without affecting food intake [51–53]. Similarly, transgenic or adenoviral overexpression of FGF21 protects against diet-induced obesity and steatosis, improves insulin sensitivity and even enhances longevity in mice [50,54–56]. Conversely, genetic deficiency or knockdown of FGF21 induces weight gain, glucose intolerance, and dyslipidemia [57,58]. In diabetic rhesus monkeys, therapeutic administration of FGF21 induced similar metabolic improvements, including decreased plasma levels of glucose, insulin, triglyceride, and LDLc, whereas it increased plasma high-density lipoprotein cholesterol (HDLc) [59]. Several mechanisms have been implicated in the pharmacological actions of FGF21, in particular the

activation of the KLB/FGFR1 complex in adipose tissue and brain [24,60–63,64▪▪,65–68].

In addition to its intricate pharmacological effects, the physiological actions of FGF21 appear equally complex. Although FGF21 is predominantly expressed in the liver, it is also expressed in other tissues, including white and brown adipose tissues (WAT and BAT), pancreas, and muscle [69]. Various types of nutrient stress have been shown to induce FGF21 expression in a tissue-specific manner. Both prolonged fasting and ketogenic diets strongly increased hepatic FGF21 expression [56,57,70]. Fasting increases FGF21 expression in PPARα-dependent manner and is closely linked with changes in lipolysis, ketogenesis, growth, torpor, and female reproduction, all considered to be aspects of the adaptive starvation response [56,57,71]. A role for FGF21 in fasting is further supported by its mutual interactions with glucagon [50,72,73]. Apart from fasting, high-carbohydrate diets and fasting-refeeding regimens also stimulate FGF21 expression in liver and WAT [74–79]. However, the physiological significance of feeding-mediated induction of FGF21 is not fully understood [74]. Finally, cold exposure increases FGF21 in BAT and WAT, where it appears to modulate thermogenic activity and browning [65,80–82].

FIBROBLAST GROWTH FACTOR 21: HUMAN ASSOCIATION STUDIES

Although FGF21 mediated aspects of the adaptive starvation response in rodents, it remains unclear if it has a similar function in humans. A ketogenic diet or fasting up to 72 h does not appear to increase serum FGF21 levels in humans [83–85]. Even in anorexia nervosa, a state of chronic nutritional deprivation, serum FGF21 levels are only slightly reduced as compared to normal-weight controls [86,87]. Only after prolonged fasting for 7 or 10 days, circulating FGF21 levels appears to be moderately increased [88,89]. In contrast to starvation, a variety of other metabolic stressors, including high-carb diets, fructose, and protein restriction, appear to modulate circulating FGF21 levels more clearly [90–95]. The identification of an FGF21 gene variant that is associated with increased sugar intake further highlights a role for FGF21 in the central regulation of carbohydrate consumption [92].

Increased levels of FGF21 are generally associated with obesity-related diseases including T2D, hypertension, coronary heart disease, and NAFLD/NASH [85,96–98]. In addition, FGF21 levels are mainly associated with BMI and adiposity, but not with insulin resistance [85,99,100]. At the same time, obesity is associated with a decrease in FGFR and KLB expression, possibly reflecting a state of receptor desensitization that is counteracted by enhanced FGF21 production [101]. It remains controversial, however, whether chronically elevated FGF21 levels reflect a state of 'FGF21 resistance', in particular as therapeutic strategies that enhanced FGF21 levels, such as gastric bypass, dietary interventions, and pharmacological administration, improve metabolic health [102–106,107▪].

FIBROBLAST GROWTH FACTOR 21: CLINICAL TRIALS

Although the development of an FGF21-based drug has not been hampered by potential mitogenic effects, native FGF21 has poor pharmacokinetic properties because of proteolytic degradation and its tendency to aggregate [108]. Efforts to optimize production and stability led to the development of LY2405319 by Eli Lilly, the first FGF21-based drug tested in humans [108]. In patients with obesity and T2D, daily injections of LY2405319 for 28 days resulted in a less atherogenic apolipoprotein profile, reduced body weight and fasting insulin levels, and increased adiponectin levels [109]. In contrast to rodents and nonhuman primates, however, no glucose-lowering effects were observed [109].

Similar efforts by Pfizer to improve FGF21 bioavailability led to the development of PF-05231023, which consists of two recombinant FGF21 molecules linked to the Fab portion of a scaffold antibody [110,111]. In obese people with T2D, PF-05231023 significantly reduced body weight, plasma triglycerides, and LDLc, while increasing HDLc. Although PF-05231023 also potently stimulated plasma adiponectin levels, glycemia was not improved [112▪,113]. Possible safety concerns of PF-05231023 treatment are its ability to affect markers of bone homeostasis and blood pressure [112▪].

More recently, the outcomes of clinical trials with pegbelfermin (BMS-986036), a polyethylene glycol-modified (PEGylated) recombinant human FGF21 analog developed by Bristol-Myers Squibb, have been published. A 12-week phase 2 study, with daily or weekly administration of pegbelfermin in patients with obesity and type 2 diabetes mellitus, showed significant improvements in HDLc and triglycerides, whereas no statistically significant improvements were found in HbA1c levels, weight loss, fasting insulin, C-peptide, and measures of hepatic insulin sensitivity (homeostatic model assessment of insulin resistance and quantitative insulin-sensitivity check index) [114]. In a 16-week phase 2a clinical trial with NASH patients, pegbelfermin significantly decreased the hepatic fat fraction, which was associated with a reduction in markers of hepatic injury and fibrosis [115▪▪].

Collectively, these studies show that FGF21-based drugs have the ability to control dyslipidemia and steatosis in humans, whereas their ability to control glycemia, similar to FGF19-based drugs, appears limited. The ongoing development of novel FGF-based therapeutics, such as the KLB/FGFR1 directed monoclonal antibody NGM313 [116–119] and FGF1-based drugs [120,121], may provide the ability to target glycemia more effectively.

FIBROBLAST GROWTH FACTOR 1: BIOLOGICAL FUNCTIONS

A role for FGF1 in metabolism was uncovered by its identification as a target of nuclear receptor PPARγ [11]. FGF1 is highly upregulated in WAT following a high-fat diet (HFD) challenge, and FGF1 knockout mice display an aggressive diabetic phenotype in response to an HFD, caused by defective adipose remodeling and expansion [11]. In a follow-up study, it was demonstrated that pharmacological administration of recombinant FGF1 effectively lowers blood glucose levels in diabetic mouse models [120,121]. Mechanistically, this glucose-lowering effect was dependent on adipose FGFR1, highlighting the role of adipose tissue function in this process [120]. The intriguing finding that intracerebroventricular injections of FGF1 can normalize blood glucose levels up to 18 weeks indicates that FGF1 also has central actions, similar to FGF19 and FGF21 [26,122,123▪▪].

In addition to its potent glucose-lowering effects, peripheral FGF1 injections also reduced obesity-related hepatic steatosis and inflammation [120,121,124]. In *ob/ob* mice, FGF1 reduced steatosis in a zonated manner, with a pronounced reduction in the periportal zone, but not pericentrally, arguing for a role of FGF1 in stimulating either fatty acid oxidation or VLDL secretion [124]. Supporting this notion, choline-deficient mice, which are defective in hepatic lipid catabolism, were refractory to the antisteatotic effects of FGF1 [124]. In contrast, the anti-inflammatory effects of FGF1 were still preserved in choline-deficient mice, suggesting that FGF1-mediated suppression of hepatic inflammation is independent of its antisteatotic effects [124].

FIBROBLAST GROWTH FACTOR 1: HUMAN ASSOCIATION STUDIES

Obesity is associated with increased FGF1 expression in both omental and subcutaneous adipose tissue [125–127]. In both humans and rodents, adipocytes have been identified as the main FGF1 producing cell type [125–127]. In contrast to the endocrine FGFs, locally produced FGF1 is not secreted into the circulation [125–127]. Interestingly, although obesity increases FGF1 expression in adipose tissue, weight loss does not reduce adipose FGF1 levels [127], supporting the notion that, in addition to promoting adipose tissue expansion, FGF1 also has a role in its contraction [11]. Different cell types and processes may be underlying the autocrine/paracrine effects of FGF1 on adipose tissue function, including activation, differentiation, and proliferation of adipocytes and endothelial cells [11,127–129].

FIBROBLAST GROWTH FACTOR 1: CLINICAL TRIALS

Owing to its potent angiogenic effects, clinical trials with FGF1 have primarily focused on the treatment of ischemia and wound healing, whereas its therapeutic potential in the development of metabolic disease in humans has not yet been reported [128,130–133]. Apart from poor stability, potential mitogenic effects of FGF1 are an important obstacle in the development of FGF1-based drugs as well [121]. Attempts to reduce mitogenic activity have yielded several FGF1 variants including R50E [134], $FGF1^{dNT}$ [120], and $FGF1^{dHBS}$ [121]. Although quantitative differences in FGF1–FGFR dimer stability clearly contribute to the mitogenic effects of wild-type and mutant FGF1 [121], qualitative differences in pathway activation, or differences in nuclear translocation [135,136], could also play a role.

CONCLUSION

Current evidence shows that FGF-based drugs can effectively ameliorate dyslipidemia, hepatic steatosis, and bile acid-related liver damage. However, antidiabetic effects, as observed in rodents and nonhuman primates, are currently not recapitulated in humans studies. The lack of these antidiabetic effects might be because of the existence of differences in glucose regulation between species [137]. In addition, it is well described that numerous pathological conditions, such as obesity [101] and inflammation [138], are associated with reduced KLB expression, which might limit FGF19 and FGF21 responsiveness. Furthermore, the use of FGF-based drugs is associated with various safety issues that might require further optimization or supportive therapies.

Acknowledgements

None.

Financial support and sponsorship

J.W.J. was supported by grants from The Netherlands Organization for Scientific Research (VICI grant 016.176.640 to

JWJ) and European Foundation for the Study of Diabetes (award supported by EFSD/Novo Nordisk).

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- ■ of special interest
- ■■ of outstanding interest

1. Nies VJ, Sancar G, Liu W, *et al.* Fibroblast growth factor signaling in metabolic regulation. Front Endocrinol (Lausanne) 2016; 6:193.
2. Markan KR, Potthoff MJ. Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis. Semin Cell Dev Biol 2016; 53:85–93.
3. Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016; 15:51–69.
4. Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015; 4:215–266.
5. Wu ZL, Zhang L, Yabe T, *et al.* The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem 2003; 278:17121–17129.
6. Kurosu H, Choi M, Ogawa Y, *et al.* Tissue-specific expression of βklotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282:26687–26695.
7. Zhang X, Ibrahimi OA, Olsen SK, *et al.* Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J Biol Chem 2006; 281:15694–15700.
8. Fon Tacer K, Bookout AL, Ding X, *et al.* Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24:2050–2064.
9. Inagaki T, Choi M, Moschetta A, *et al.* Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2:217–225.
10. Hotta Y, Nakamura H, Konishi M, *et al.* Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009; 150:4625–4633.
11. Jonker JW, Suh JM, Atkins AR, *et al.* A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012; 485:391–394.
12. McWhirter JR, Weiner JA, Chun J, Murre CG. A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development 1997; 124:3221–3232.
13. Nishimura T, Utsunomiya Y, Hoshikawa M, *et al.* Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta – Gene Struct Expr 1999; 1444:148–151.
14. Lundåsen T, Gälman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260:530–536.
15. Perez MJ, Britz O. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009; 15:1677–1689.
16. Kliewer SA, Mangelsdorf DJ. Bile acids as hormones: the FXR-FGF15/19 pathway. Dig Dis 2015; 33:327–331.
17. Fu L, John LM, Adams SH, *et al.* Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145:2594–2603.
18. Tomlinson E. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143:1741–1747.
19. Zhou M, Learned RM, Rossi SJ, *et al.* Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun 2017; 1:1024–1042.
20. Massafra V, Milona A, Vos HR, *et al.* Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation. PLoS One 2017; 12:1–18.
21. Hansen AM, Vienberg SG, Lykkegaard K, *et al.* Differential receptor selectivity of the FGF15/FGF19 orthologues determines distinct metabolic activities in db/db mice. Biochem J 2018; 475:2985–2996.
22. Kir S, Beddow SA, Samuel VT, *et al.* FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (80–) 2011; 331:1621–1624.
23. Potthoff MJ, Boney-Montoya J, Choi M, *et al.* FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab 2011; 13:729–738.
24. Lan T, Morgan DA, Rahmouni K, *et al.* FGF19, FGF21, and an FGFR1/β-klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab 2017; 26:709.e3–718.e3.
25. Morton GJ, Matsen ME, Bracy DP, *et al.* FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 2013; 123:4799–4808.
26. Perry RJ, Lee S, Ma L, *et al.* FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis. Nat Commun 2015; 6:1–10.
27. Lips MA, De Groot GH, Berends FJ, *et al.* Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects. Clin Endocrinol (Oxf) 2014; 81:862–870.
28. Barrera F, Azócar L, Molina H, *et al.* Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann Hepatol 2015; 14:710–721.
29. Gerhard GS, Styer AM, Wood GC, *et al.* A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-y gastric bypass. Diabetes Care 2013; 36:1859–1864.
30. Sachdev S, Wang Q, Billington C, *et al.* FGF 19 and bile acids increase following roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes. Obes Surg 2016; 26:957–965.
31. Bertolini A, van de Peppel IP, Doktorova-Demmin M, *et al.* Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol. Am J Physiol Gastrointest Liver Physiol 2019; 316:G404–G411.
32. Barutcuoglu B, Basol G, Cakir Y, *et al.* Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann Clin Lab Sci 2011; 41:390–396.
33. Gómez-Ambrosi J, Gallego-Escuredo JM, Catalán V, *et al.* FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically induced weight loss. Clin Nutr 2017; 36:861–868.
34. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49:1228–1235.
35. Wunsch E, Milkiewicz M, Wasik U, *et al.* Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep 2015; 5:1–13.
36. Zhou M, Luo J, Chen M, *et al.* Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15. J Hepatol 2017; 66:1182–1192.
37. Jørgensen NB, Dirksen C, Bojsen-Møller KN, *et al.* Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab 2015; 100:E396–406.
38. Nicholes K, Guillet S, Tomlinson E, *et al.* A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160:2295–2307.
39. ■■ Zhou M, Yang H, Learned RM, *et al.* Noncell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. Nat Commun 2017; 8:1–16.

This article demonstrates that FGF19 drives hepatocarcinogenesis through IL6/STAT3 acitivity.

40. Luo J. A nontumorigenic variant of FGF19 treats cholestaic liver disease. Sci Transl Med 2014; 6:1–12.
41. Gälman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003; 44:859–866.
42. ■■ Harrison SA, Rinella ME, Abdelmalek MF, *et al.* NGM282 for treatment of nonalcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2018; 391:1174–1185.

This is the first clinical trials which demonstrate that FGF19-mimetics can reduce liver fat content and liver damage in patients with NASH.

43. Zhou M, Learned RM, Rossi SJ, *et al.* Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 2016; 63:914–929.
44. ■■ Rinella ME, Trotter JF, Abdelmalek MF, *et al.* Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. J Hepatol 2018. S0168-8278(18)32615-1.

This article shows that NGM282-related elevation of LDL in NASH patients can be counteracted by concomitant rosuvastatin use.

45. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237–267.
46. Lammers WJ, Van Buuren HR, Hirschfield GM, *et al.* Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147:1338.e5–1349.e5.
47. ■■ Mayo MJ, Wigg AJ, Leggett BA, *et al.* NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun 2018; 2:1037–1050.

This clinical trials shows that FGF19-mimetics have potential in the treatment of cholestatic liver diseases.

48. Hirschfield GM, Chazouillères O, Drenth JP, *et al.* Effect of NGM282, an ■■ FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 2019; 70:483–493.

This clinical trials shows that FGF19-mimetics have potential in the treatment of cholestatic liver diseases.

49. Oduyebo I, Camilleri M, Nelson AD, *et al.* Effects of NGM282, an FGF19 ■ variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. Am J Gastroenterol 2018; 113:725–734.

This article shows that FGF19-mimetics also affect intestinal function in a bile acid-independent manner.

50. Kharitonenkov A, Shiyanova TL, Koester A, *et al.* FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115:1627–1635.
51. Coskun T, Bina HA, Schneider MA, *et al.* Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149:6018–6027.
52. Xu J, Lloyd DJ, Hale C, *et al.* Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58:250–259.
53. Muise ES, Souza S, Chi A, *et al.* Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One 2013; 8:e73011.
54. Jimenez V, Jambrina C, Casana E, *et al.* FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 2018; 10:e8791.
55. Zhang Y, Xie Y, Berglund ED, *et al.* The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 2012; 2012:1–14.
56. Inagaki T, Dutchak P, Zhao G, *et al.* Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5:415–425.
57. Badman MK, Pissios P, Kennedy AR, *et al.* Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5:426–437.
58. Badman MK, Koester A, Flier JS, *et al.* Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009; 150:4931–4940.
59. Kharitonenkov A, Wroblewski VJ, Koester A, *et al.* The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148:774–781.
60. Ding X, Boney-Montoya J, Owen BM, *et al.* βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab 2012; 16:387–393.
61. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. FGF21 requires βklotho to act in vivo. PLoS One 2012; 7:e49977.
62. Holland WL, Adams AC, Brozinick JT, *et al.* An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 2013; 17:790–797.
63. Lin Z, Tian H, Lam KS, *et al.* Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013; 17:779–789.
64. BonDurant LD, Ameka M, Naber MC, *et al.* FGF21 regulates metabolism ■■ through adipose-dependent and -independent mechanisms. Cell Metab 2017; 25:935.e4–944.e4.

This article shows an interesting view on multiple mechanisms involved in FGF21 action.

65. Sarruf DA, Thaler JP, Morton GJ, *et al.* Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010; 59:1817–1824.
66. Owen BM, Ding X, Morgan DA, *et al.* FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 2014; 20:670–677.
67. Bookout AL, de Groot MH, Owen BM, *et al.* FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 2013; 19:1147–1152.
68. Emanuelli B, Vienberg SG, Smyth G, *et al.* Interplay between FGF21 and insulin action in the liver regulates metabolism. J Clin Invest 2014; 124:515–527.
69. Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol 2016; 78:223–241.
70. Asrih M, Altirriba J, Rohner-Jeanrenaud F, Jornayvaz FR. Ketogenic diet impairs FGF21 signaling and promotes differential inflammatory responses in the liver and white adipose tissue. PLoS One 2015; 10:e0126364.
71. Lundåsen T, Hunt MC, Nilsson LM, *et al.* PPARα is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 2007; 360:437–440.
72. Berglund ED, Kang L, Lee-Young RS, *et al.* Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo. Am J Physiol Metab 2010; 299:E607–E614.
73. Habegger KM, Stemmer K, Cheng C, *et al.* Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013; 62:1453–1463.
74. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012; 26:312–324.
75. Fontana L, Cummings NE, Arriola Apelo SI, *et al.* Decreased consumption of branched-chain amino acids improves metabolic health. Cell Rep 2016; 16:520–530.
76. Cummings NE, Williams EM, Kasza I, *et al.* Restoration of metabolic health by decreased consumption of branched-chain amino acids. J Physiol 2018; 596:623–645.
77. Maida A, Zota A, Vegiopoulos A, *et al.* Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance. J Nutr Biochem 2018; 57:189–196.
78. Oishi K, Konishi M, Murata Y, Itoh N. Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice. Biochem Biophys Res Commun 2011; 412:396–400.
79. Chung H, Chou W, Sears DD, *et al.* Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity. Metabolism 2016; 65:1743–1754.
80. Chartoumpekis D, Habeos I. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med 2011; 17:736–740.
81. Hondares E, Iglesias R, Giralt A, *et al.* Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 2011; 286:12983–12990.
82. Fisher FM, Kleiner S, Douris N, *et al.* FGF21 regulates PGC-1 and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 2012; 26:271–281.
83. Christodoulides C, Dyson P, Sprecher D, *et al.* Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009; 94:3594–3601.
84. Andersen B, Beck-Nielsen H, Højlund K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf) 2011; 75:514–519.
85. Dushay J, Chui PC, Gopalakrishnan GS, *et al.* Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139:456–463.
86. Fazeli PK, Faje AT, Cross EJ, *et al.* Serum FGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa. Bone 2015; 77:6–11.
87. Dostálová I, Kaválková P, Haluzíková D, *et al.* Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93:3627–3632.
88. Fazeli PK, Lun M, Kim SM, *et al.* FGF21 and the late adaptive response to starvation in humans. J Clin Invest 2015; 125:4601–4611.
89. Gälman C, Lundåsen T, Kharitonenkov A, *et al.* The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab 2008; 8:169–174.
90. Solon-Biet SM, Cogger VC, Pulpitel T, *et al.* Defining the nutritional and metabolic context of FGF21 using the geometric framework. Cell Metab 2016; 24:555–565.
91. ter Horst KW, Gilijamse PW, Demirkiran A, *et al.* The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans. Mol Metab 2017; 6:1493–1502.
92. Frayling TM, Beaumont RN, Jones SE, *et al.* A common allele in FGF21 associated with sugar intake is associated with body shape, lower total body-fat percentage, and higher blood pressure. Cell Rep 2018; 23:327–336.
93. Lundsgaard AM, Fritzen AM, Sjøberg KA, *et al.* Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. Mol Metab 2017; 6:22–29.
94. Samms RJ, Lewis JE, Norton L, *et al.* FGF21 is an insulin-dependent postprandial hormone in adult humans. J Clin Endocrinol Metab 2017; 102: 3806–3813.
95. Gosby AK, Lau NS, Tam CS, *et al.* Raised FGF-21 and triglycerides accompany increased energy intake driven by protein leverage in lean, healthy individuals: a randomised trial. PLoS One 2016; 11:1–16.
96. Domouzoglou EM, Naka KK, Vlahos AP, *et al.* Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21. Am J Physiol Circ Physiol 2015; 309:H1029–H1038.
97. Chen C, Cheung BM, Tso AW, *et al.* High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34:2213–2215.
98. Bobbert T, Schwarz F, Fischer-Rosinsky A, *et al.* Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36:145–149.
99. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, *et al.* Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32:1542–1546.
100. Mashili FL, Ramaiya K, Lutale J, *et al.* Adiposity is a key correlate of circulating fibroblast growth factor-21 levels in african males with or without type 2 diabetes mellitus. J Obes 2018; 2018:1–8.
101. Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, *et al.* Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes 2015; 39:121–129.
102. Nygaard EB, Ørskov C, Almdal T, *et al.* Fasting decreases plasma FGF21 in obese subjects and the expression of FGF21 receptors in adipose tissue in both lean and obese subjects. J Endocrinol 2018; 239:73–80.

103. Escoté X, Félix-Soriano E, Gayoso L, *et al.* Effects of EPA and lipoic acid supplementation on circulating FGF21 and the fatty acid profile in overweight/obese women following a hypocaloric diet. Food Funct 2018; 9:3028–3036.

104. Harris LA, Smith GI, Mittendorfer B, *et al.* Roux-en-Y gastric bypass surgery has unique effects on postprandial FGF21 but not FGF19 secretion. J Clin Endocrinol Metab 2017; 102:3858–3864.

105. Harris LL, Smith GI, Patterson BW, *et al.* alterations in 3-hydroxyisobutyrate and fgf21 metabolism are associated with protein ingestion-induced insulin resistance. Diabetes 2017; 66:1871–1878.

106. Markova M, Pivovarova O, Hornemann S, *et al.* Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes. Gastroenterology 2017; 152:571.e8–585.e8.

107. ▪ Markan KR. Defining 'FGF21 Resistance' during obesity: controversy, criteria and unresolved questions. F1000Research 2018; 7:289.

This article sheds light on an interesting phenomenon that needs further investigation.

108. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol Metab 2014; 3:221–229.

109. Gaich G, Chien JY, Fu H, *et al.* The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18:333–340.

110. Dong JQ, Rossulek M, Somayaji VR, *et al.* Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study. Br J Clin Pharmacol 2015; 80:1051–1063.

111. Huang J, Ishino T, Chen G, *et al.* Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther 2013; 346:270–280.

112. ▪ Kim AM, Somayaji VR, Dong JQ, *et al.* Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in nonhuman primates. Diabetes, Obes Metab 2017; 19:1762–1772.

This article argues to take side-effects by FGF21 analogue treatment into consideration.

113. Talukdar S, Zhou Y, Li D, *et al.* A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in nonhuman primates and type 2 diabetic subjects. Cell Metab 2016; 23:427–440.

114. Charles ED, Neuschwander-Tetri BA, Pablo Frias J, *et al.* Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity 2018; 27:41–49.

115. ▪▪ Sanyal A, Charles ED, Neuschwander-Tetri BA, *et al.* Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with nonalcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 2018; 392:2705–2717.

This article is showing positive effects of an FGF21 analogue in NAFLD patients.

116. Shankar S, Bashir MR, Baxter BA, *et al.* NGM313, a novel once-monthly activator of b klotho-FGFR1c, significantly reduces hepatic steatosis and key biomarkers of nonalcoholic steatohepatitis. Poster presented at: The Liver Meeting of The *American Association for the Study of Liver Diseases (AASLD)*; San Francisco, 2018.

117. Bao L, Yin J, Gao W, *et al.* A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of nonalcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol 2018; 175:3379–3393.

118. Yin J, Bao L, Chen R, *et al.* Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis. BioChimie 2018; 151:166–175.

119. Weng Y, Ishino T, Sievers A, *et al.* Glyco-engineered long acting FGF21 variant with optimal pharmaceutical and pharmacokinetic properties to enable weekly to twice monthly subcutaneous dosing. Sci Rep 2018; 8:4241–4255.

120. Suh JM, Jonker JW, Ahmadian M, *et al.* Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014; 513:436–439.

121. Huang Z, Tan Y, Gu J, *et al.* Uncoupling the mitogenic and metabolic functions of FGF1 by tuning FGF1-FGF receptor dimer stability. Cell Rep 2017; 20:1717–1728.

122. Scarlett JM, Rojas JM, Matsen ME, *et al.* Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat Med 2016; 22:800–806.

123. ▪▪ Scarlett JM, Muta K, Brown JM, *et al.* Peripheral mechanisms mediating the sustained anti-diabetic action of FGF1 in the brain. Diabetes 2018; 68:654–664.

This article explores the mechanism behind sustained glycemic control after central FGF1 administration.

124. Liu W, Struik D, Nies VJ, *et al.* Effective treatment of steatosis and steatohepatitis by fibroblast growth factor 1 in mouse models of nonalcoholic fatty liver disease. Proc Natl Acad Sci 2016; 113:2288–2293.

125. Gómez-Ambrosi J, Catalán V, Diez-caballero A, *et al.* Gene expression profile of omental adipose tissue in human obesity. FASEB J 2003; 18:215–217.

126. Lee YH, Nair S, Rousseau E. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs nonobese Pima Indians: increased expression of inflammation-related genes. Diabetologia 2005; 48:1776–1783.

127. Mejhert N, Galitzky J, Pettersson AT, *et al.* Mapping of the fibroblast growth factors in human white adipose tissue. J Clin Endocrinol Metab 2010; 95:2451–2457.

128. Schumacher B, Pecher P, Specht BU, *et al.* Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645–650.

129. Hutley L, Shurety W, Newell F, *et al.* Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes 2004; 53:3097–3106.

130. Nikol S, Baumgartner I, Van Belle E, *et al.* Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16:972–978.

131. Belch J, Hiatt WR, Baumgartner I, *et al.* Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377:1929–1937.

132. Baumgartner I, Chronos N, Comerota A, *et al.* Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia. Mol Ther 2009; 17:914–921.

133. Comerota AJ, Throm RC, Miller KA, *et al.* Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35:930–936.

134. Mori S, Tran V, Nishikawa K, *et al.* A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. PLoS One 2013; 8:e57927.

135. Zakrzewska M, Sørensen V, Jin Y, *et al.* Translocation of exogenous FGF1 into cytosol and nucleus is a periodic event independent of receptor kinase activity. Exp Cell Res 2011; 317:1005–1015.

136. Zakrzewska M, Marcinkowska E, Wiedlocha A. FGF-1: from biology through engineering to potential medical applications. Crit Rev Clin Lab Sci 2008; 45:91–135.

137. Chandrasekera PC. Of rodents and men: species-specific glucose regulation and type 2 diabetes research. ALTEX 2014; 31:157–176.

138. Díaz-Delfín J, Hondares E, Iglesias R, *et al.* TNF-α represses β-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 2012; 153:4238–4245.